What is the appropriate management for a patient with psoriasis who has recurrent severe ankle swelling and pain, negative imaging, a prior gout diagnosis despite normal uric acid levels, and has not responded to colchicine or indomethacin?

This patient almost certainly has psoriatic arthritis, not gout, and needs urgent rheumatology referral for DMARD therapy

The clinical picture is unmistakable: a patient with established psoriasis experiencing recurrent severe monoarticular ankle inflammation that fails to respond to colchicine and indomethacin, with persistently normal uric acid levels—this is psoriatic arthritis until proven otherwise. The prior "gout" diagnosis appears to be a misdiagnosis that has delayed appropriate treatment for years.

Why This Is Psoriatic Arthritis, Not Gout

Key diagnostic clues:

• Established psoriasis is present—the single most important risk factor for psoriatic arthritis
• Normal uric acid levels consistently—while gout can occur with normal serum urate during flares 1, the complete lack of response to colchicine and indomethacin over multiple episodes makes gout extremely unlikely 2
• Recurrent monoarthritis affecting the same joint repeatedly is a classic psoriatic arthritis pattern
• Treatment failure with standard gout therapy (colchicine, indomethacin) strongly argues against gout as the primary diagnosis

The evidence shows that psoriasis patients can develop hyperuricemia from increased epidermal cell turnover 3, but this does not mean every inflammatory arthritis in a psoriasis patient is gout. The lack of therapeutic response is the critical distinguishing feature here.

Immediate Management Algorithm

Step 1: Confirm the diagnosis

• Refer urgently to rheumatology (do not delay treatment)
• Check inflammatory markers: ESR, CRP (typically elevated in active psoriatic arthritis) 4
• Consider joint ultrasound or MRI if available (may show enthesitis, synovitis, or erosions even when X-rays are negative)
• Synovial fluid analysis if joint effusion present (to definitively exclude crystals)

Step 2: Initiate DMARD therapy rapidly

According to the 2024 EULAR guidelines 4, for monoarthritis/oligoarthritis with recurrent severe episodes (which represents poor prognostic factors), a conventional synthetic DMARD (csDMARD) should be initiated rapidly.

Start methotrexate as first-line therapy given the patient has psoriasis:

• Begin 10-15 mg weekly, titrate to 20-25 mg weekly
• Add folic acid 1 mg daily (or 5 mg weekly, day after methotrexate)
• Methotrexate is specifically preferred when there is "clinically relevant skin involvement" 4

Step 3: Bridge therapy for acute symptoms

While awaiting DMARD effect (takes 6-12 weeks):

• Intra-articular corticosteroid injection into the affected ankle provides rapid relief and is specifically recommended as adjunctive therapy 4
• Short course of oral prednisone (20-40 mg daily, taper over 1-2 weeks) if injection not feasible
• NSAIDs may provide some symptomatic relief but are insufficient as monotherapy 4

Step 4: Escalate if inadequate response

If after 3-6 months on optimized methotrexate (20-25 mg weekly) the patient continues having severe flares:

Advance to biologic DMARD therapy 4:

• IL-17 inhibitors (secukinumab, ixekizumab) or IL-12/23 inhibitors (ustekinumab) are preferred when significant skin involvement exists
• TNF inhibitors (adalimumab, etanercept) are also effective alternatives
• The 2024 guidelines specifically state biologics should be commenced after inadequate response to at least one csDMARD 4

Critical Pitfalls to Avoid

Do not continue treating this as gout:

• Colchicine and NSAIDs alone will not control psoriatic arthritis
• Urate-lowering therapy (allopurinol, febuxostat) is irrelevant if this is not gout
• Repeated failed treatments with gout medications should trigger diagnostic reconsideration

Do not delay DMARD initiation:

• Psoriatic arthritis causes irreversible joint damage and structural changes 4
• The goal is to prevent structural damage, not just symptom control
• Early aggressive treatment improves long-term outcomes for quality of life and function 4

Do not rely on imaging alone:

• Negative X-rays do not exclude psoriatic arthritis—early disease may show no radiographic changes
• Ultrasound or MRI are more sensitive for detecting synovitis and enthesitis

Special Considerations

The evidence shows that biological therapy effectively reduces systemic inflammation in psoriasis but does not modify serum uric acid levels 5, which further supports that treating the underlying psoriatic arthritis (not hyperuricemia) is the correct approach.

While rare cases of overlapping gout and psoriatic arthritis exist 6, 3, the complete absence of response to standard gout therapy over multiple episodes makes pure gout diagnosis untenable. If there is genuine diagnostic uncertainty after rheumatology evaluation, joint aspiration during an acute flare to look for monosodium urate crystals would be definitive.

The treatment target is remission or minimal disease activity 4, assessed by regular monitoring and therapy adjustment. This patient has suffered unnecessarily for years with an incorrect diagnosis—prompt recognition and treatment of psoriatic arthritis will dramatically improve their quality of life and prevent permanent joint damage.